Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D1 dopamine program
- Development stage
- Preclinical
- Lead developer
- ConfometRx
- Modality
- Small Molecules
01
Overview
The D1 dopamine program is a small molecule drug candidate developed by ConfometRx for the treatment of Parkinson's Disease. It targets the D1 dopamine receptor, a G protein-coupled receptor (GPCR) that plays a critical role in the central nervous system, particularly in the regulation of motor function and reward pathways. The program leverages ConfometRx's proprietary structural biology platform to design molecules with high specificity for GPCR targets. Currently, the candidate is undergoing IND-enabling studies to support future clinical development.
- Other names
- D1D-1D 1
02
Targets
DRD1 (Dopamine D1 Receptor)
Beyond the preview
Go deeper on D1 dopamine program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D1 dopamine program.